Midterm Review of the Global Measles and Rubella Strategic Plan W. A. Orenstein, MD SAGE Geneva, 19 October 2016

Similar documents
Measles and Rubella Global Strategic Plan Midterm Review

Polio post-certification strategy

3. CONCLUSIONS AND RECOMMENDATIONS

Measles and Rubella Global Update SAGE 19 October 2017

GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights

Measles and Rubella Global Update SAGE April 2018

Polio and routine immunisation Alan Brooks

Thank you for joining, the M&RI webinar will begin shortly

Report to the Board June 2016

Ensuring the quality of polio outbreak response activities: A rationale and guide for 3 month, quarterly and 6 month independent assessments

DEVELOPING A GLOBAL IMMUNIZATION STRATEGY

FISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated ) USAID Global Health Programs (GHP) and State Department

ANNEX Page. AFR/RC61/11 4 July 2011 ORIGINAL: ENGLISH REGIONAL COMMITTEE FOR AFRICA

Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office

Report to the. GAVI Alliance Board June 2013

Gavi Risk Appetite Statement Version 2.0

How to present the European Vaccine Action Plan (EVAP)

Gavi Alliance Strategy : Goal level indicators and disease dashboard

Report to the Board 7-8 December 2016

POLIO POST-CERTIFICATION STRATEGY. Summary overview 8 August 2017

Progress reports on selected Regional Committee resolutions:

FINANCIAL RESOURCE REQUIREMENTS

Poliomyelitis eradication in the WHO European Region

Copenhagen, Denmark, September August Malaria

Targeted Diseases and Immunization. Strategic plan

GAVI, THE VACCINE ALLIANCE

Report to the Board June 2015

Sudan EPI Benefits From Polio Eradication Program

Polio & routine immunisation Alan Brooks

CONTENTS. Paragraphs I. BACKGROUND II. PROGRESS REPORT ON THE AFRICAN REGIONAL IMMUNIZATION STRATEGIC PLAN

10.4 Advocacy, Communication and Social Mobilization Working Group: summary strategic plan,

Global Immunizations & UNICEF s Role Dr. Robin Nandy Principal Advisor & Chief of Immunizations UNICEF Headquarters

Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization Agenda October 2018 CICG, Geneva, Switzerland Version: 19 October 2018

Measles Containing Vaccines. UNICEF Supply Division Industry Consultation Meeting January 2012

Guidance to Increasing Population Immunity Against Measles and Rubella

1. The World Bank-GAVI Partnership and the Purpose of the Review

2016 NON FINANCIAL RESOURCE REQUIREMENTS GPEI DONOR CONTRIBUTIONS

CLOSING MR IMMUNITY GAPS EXPERIENCES FROM THE REGIONS MALAWI. Geoffrey Zimkambani Chirwa EPI Manager

USAID Progress: The U.S. National Vaccine Plan of 1994

Fifth report of Committee A

TERMS OF REFERENCE. Regional Immunization Program. Department of Family, Gender and Life Course

WHO position paper on rubella vaccines

Report to the Board June 2016

GAVI Role in IPV Introductions

Strategy and documentation of the measles and rubella elimination in the WHO Regional Office for Europe

POLIO ERADICATION AND POST-CERTIFICATION STRATEGY

Polio Transition Planning: Risks and opportunities of transitioning resources to non-polio public health interventions

Measles-Containing Vaccines: Supply & Demand Outlook. UNICEF Supply Division

Çeşme Izmir, Turkey, September 2013

KEY ISSUES IN IMMUNIZATION IN AFRICA

An aggressive approach for measles outbreak among adolescents in Barranquilla, Colombia, 2011

GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012

Report to the Board 6-7 June 2018

REGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC. second edition

Monitoring results: goals, strategic objectives and indicators

Strengthening regional health security: Emerging diseases and disaster preparedness and response

Government of Bangladesh

Measles and Rubella Initiative Outbreak Response Fund Standard Operating Procedures, effective 01 April 2017

WHO Consultation on universal access to core malaria interventions in high burden countries: main conclusions and recommendations

39th Meeting of the UNAIDS Programme Coordinating Board Geneva, Switzerland. 6-8 December 2016

Global Partners' Group

50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE

GAVI S CONTINUED ROLE IN YELLOW FEVER CONTROL

Report to the. GAVI Alliance Board June Alan Brooks, Special Adviser for Immunisation

FAO of the UN, WHO and OIE with the collaboration of UNSIC and UNICEF. Background Paper

SUCCESSFULLY TRANSITIONING NIGERIA FROM GAVI SUPPORT

ADVOCACY IN ACTION TO ACHIEVE GENDER EQUALITY AND THE SUSTAINABLE DEVELOPMENT GOALS IN KENYA

Progress report on eradication of poliomyelitis: regional implications of the endgame strategy

Expanded Programme on Immunization

Polio and measles control: opportunities and threats for health systems

10 th Annual African Vaccinology Course (AAVC) Cape Town 10 November 2014

Message from. Dr Samlee Plianbangchang Regional Director, WHO South-East Asia. At the. Regional Review Meeting on Immunization

Polio Eradication & Endgame Strategic Plan Executive Summary

International PolioPlus Committee PolioPlus Facts and Figures June Rotary s financial contribution to the polio eradication effort:

2016 United Nations Political Declaration on Ending AIDS sets world on the Fast-Track to end the epidemic by 2030

Introduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa

Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework

Ending Malaria in Nigeria: The WHO Agenda

Gavi s private sector engagement approach

Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch

Preventing disease Promoting and protecting health

STRENGTHENING HEALTH SYSTEMS: TOWARD UNIVERSAL HEALTH COVERAGE & GLOBAL HEALTH SECURITY

Johns Hopkins Vaccine Initiative 2013 Vaccine Internship Experience at WHO (VIEW) Sample Internship Descriptions

5 th Islamic Conference of Health Ministers. Resolution. Istanbul, Turkey November 2015 (5-7 Safar 1437H)

STRATEGIC PLAN

Multisectoral action for a life course approach to healthy ageing

Monitoring of the achievement of the health-related Millennium Development Goals

POLIOMYELITIS ERADICATION: PROGRESS REPORT. Information Document CONTENTS BACKGROUND PROGRESS MADE NEXT STEPS... 12

Dr. Collins Tabu 24 th April 2018 Nairobi, Kenya

Photo courtesy Conrad N. Hilton Foundation. EVALUATION OF THE Conrad N. Hilton Foundation Chronic Homelessness Initiative 2015 REPORT

Preparing Influenza Pandemic Preparedness Plans: A Step-by-Step Approach

Report for the SAGE Working Group on Measles and Rubella April 2018, Geneva. The Roadmap to Immunity

Global reductions in measles mortality and the risk of measles resurgence

Global Immunization Overview. Thomas Cherian Expanded Programme on Immunization WHO, Geneva

Global Polio Eradication, Progress, Impact of Ebola, Risks & Opportunities. Polio Partners Group 8 December 2014

Lessons learned and strategies for maintaining measles elimination Alberta s perspective

Manojkumar Choudhary 1, Roma Solomon, Jitendra Awale and Rina Dey

Challenges of building a new vaccine delivery platform for LMICs

Summary of the Meeting of the Strategic Advisory Group of Experts on immunization, April 2018

Transcription:

Midterm Review of the Global Measles and Rubella Strategic Plan 2012 2020 W. A. Orenstein, MD SAGE Geneva, 19 October 2016 1

Outline Strategic Plan 2012-2020 Progress toward milestones and goals Objectives of Midterm Review Process and oversight Eight sections of the report Findings and conclusions Recommendations Five core strategies Building on the polio transition Governance Resource mobilization Summary 2

Success in reaching 2015 goal and milestones 2015 Goal or Milestone Evaluation (based on 2015 data) Achieve > 95% reduction in estimated measles mortality compared to 2000 Reduce annual measles incidence to less than 5 cases/million & maintain that level Achieve at least 90% MCV1 coverage nationally, and > 80% coverage in every district or equivalent administrative unit. Achieve at least 95% coverage with M, MR or MMR during SIAs in every district. Establish a rubella/crs elimination goal in at least three additional WHO regions (i.e., in addition to the AMR and EUR that had established goals before 2012). Establish a target date for the global eradication of measles. Reduction of 79%* Global incidence of 36 per million 119 (61%) countries have MCV1 coverage > 90% at national level. Of 104 SIAs from 2013-2015, 52 (50%) had a reported coverage of 95%. Only 19 conducted a post- SIA coverage survey; 9 (47%) reached 95% national coverage One additional region, WPR, has established a rubella elimination goal but no date is associated with it No target date for global measles eradication established * Preliminary data Legend Little or no progress Some progress but inadequate to meet 2015 goals 3

Objectives of Review To provide a candid review of progress toward, and key reasons for not attaining, 2015 goals To assess the quality of implementation of strategies and principles, and recommend refinements To formulate lessons learned and priorities for 2016 2020 4

Process, oversight and endorsement Process 5 external consultants + secretariat Global, regional and country level assessment 1-2 countries per Region Focus on strategy Desk review; interviews with key informants Oversight and endorsement Oversight by SAGE Working Group (Measles and Rubella) 2016 Endorsement by SAGE and World Health Assembly 2017 (as part of GVAP Report) 5

Report: eight sections 1. Monitor disease using effective surveillance, and evaluate programmatic efforts 2. Achieve and maintain high levels of population immunity by providing two doses of measles and rubella containing vaccines 3. Develop and maintain outbreak preparedness, respond rapidly to outbreaks and manage cases 4. Communicate and engage to build public confidence and demand for immunization 5. Perform research and development to support cost-effective operations and improve vaccination and diagnostic tools 6. Building on the polio transition 7. Governance 8. Resource mobilization and advocacy 6

Major findings and conclusions (1) Tremendous progress made towards both measles and rubella elimination since 2001 Significant gains also made during 2012 2015 23/194 WHO Member States introduced MCV2 Global MCV2 coverage rose from 48% to 61% 17 countries introduced RCV in their schedule Global RCV coverage rose from 39% to 46% 4.25 million deaths estimated to have been averted during 2012 2014 relative to no vaccination However, neither measles nor rubella elimination on track to achieve ambitious goals laid out in the Global Measles and Rubella Strategic Plan, 2012-2020 7

Major findings and conclusions (2) Basic strategies articulated are sound Full implementation has been limited by lack of country ownership and global political will, reflected in insufficient resources In principle, the 2020 goals can still be reached but doing so would require a substantial escalation of political will and resources heavy reliance on supplementary immunization activities (SIAs) 8

Major findings and conclusions (3) It is premature to set a timeframe for measles eradication at this point Instead, the annual review of progress toward the Global Vaccine Action Plan (GVAP) goals should be used to assess progress toward measles elimination A determination should be made, not later than 2020, whether a formal global goal for measles eradication should be set with timeframes for achievement In the meantime, all regions should work toward achieving the regional elimination goals 9

Major findings and conclusions (4) Re-orient program to increase emphasis on surveillance so that programmatic and strategic decisions can be guided by disease data A focus on measles surveillance can help detect populations unreached by immunization systems and, by extension, program weaknesses Working to achieve measles and rubella elimination can strengthen health systems in general and immunization systems in particular 10

Major findings and conclusions (5) Strengthening of immunization systems is critical to achieving regional elimination goals. There must be a focus on how working to achieve measles and rubella eradication can help strengthen health systems in general and immunization systems in particular Measuring coverage with measles and rubella containing vaccines, while important, is not the best indicator of progress toward measles and rubella control/elimination. Disease incidence is the most important indicator of progress 11

Major findings and conclusions (6) There is an urgent need to strengthen the collection and use of surveillance data to better guide program strategy and implementation A costed implementation plan in response to these recommendations should be developed not later than twelve months after the release of this report. 12

Monitoring Disease Using Effective Surveillance - recommendations (1) A top priority for achieving the goals of the Measles Rubella Strategic Plan is to enhance case-based, laboratory-supported surveillance for measles and rubella All countries must implement case-based surveillance for measles and rubella Cases should be reported weekly from country to region A working group on surveillance and outbreak investigation should be developed Protocols need to be developed to guide how to conduct, interpret and disseminate data analysis results for policy E.g., who is transmitting to whom Exposure settings 13

Monitoring Disease Using Effective Surveillance - recommendations (2) Countries need to dedicate resources for surveillance and partners need to supplement resources as needed, including resources for staffing, lab support, training, and other operational costs. Countries eligible for funding from Gavi should consider using Health System and Immunization Strengthening (HSIS) funding to support the surveillance infrastructure 14

Monitoring Disease Using Effective Surveillance - recommendations (3) CRS Surveillance, either sentinel or national level, should be implemented, especially in countries using MR As the GPEI winds down, at a minimum the current level of measles and rubella surveillance should be maintained. Wherever possible, the polio transition should be capitalized on to further strengthen measles and rubella surveillance, as well as surveillance for other VPDs Both in outbreak investigations as well as in routine surveillance, all cases should be classified as preventable or non-preventable. A preventable case represents a program failure, i.e., a person who should have been vaccinated but was not. A non-preventable case is one for whom the current strategy does not offer direct protection. Vaccine-eligible persons of unknown vaccination status should be considered unvaccinated and thus preventable cases. 15

Achieve and Maintain High Levels of Population Immunity - recommendations (1) Measles and rubella control and elimination activities at national level should be located within the overall immunization program Two doses of measles containing vaccine (MCV) or measles-rubella containing vaccine (MRCV) delivered through ongoing services is the standard for all national immunization programs. Preventive SIAs should be conducted on a regular basis, if routine 2 dose coverage is insufficient to achieve and maintain high population immunity Efforts to enhance measles and rubella prevention should take into account the importance of strengthening the overall immunization delivery system. 16

Achieve and Maintain High Levels of Population Immunity - recommendations (2) A standardized method to categorize countries based on their level of disease control and likelihood of achieving and sustaining achievement of measles and rubella elimination goals should be developed. Immunization and surveillance strategies should be tailored to the country categorization. All countries should institute a school entry check for immunization, including vaccination against measles and rubella as well as against other VPDs. Vaccination should be provided to children who have not received vaccine. Every opportunity should be taken to vaccinate people not adequately vaccinated, particularly those under 15 years of age. 17

Outbreak preparedness and response - recommendations (1) Emphasis should be placed on prevention of outbreaks through monitoring of risk status and increased attention to vaccination of underserved communities and high risk settings. Use of the district level program risk assessment tool should be considered All measles and rubella outbreaks should be promptly investigated and used to develop a susceptibility profile of the population Based on existing experience, training materials should be developed for use at global, regional and country levels to perform outbreak investigations, as well as to understand the underlying reasons that outbreaks are occurring and disseminate investigation results. 18

Outbreak preparedness and response - recommendations (2) There must be adequate financial, human and laboratory resources to conduct outbreak investigations Gavi-eligible countries should consider HSIS funds Resources are urgently needed for non-gavi eligible countries Countries should develop national Measles and Rubella Outbreak Preparedness and Response plans. Funding requirements for the implementation of these Plans should be included in measles and rubella program Financial Resource Requirements. When outbreaks are detected, in addition to investigation, countries should take steps to mitigate the outbreak through vaccination. The magnitude of the response should be based on the characteristics of the outbreak, the stage of measles and rubella control, and the category to which countries belong. 19

Communication recommendations (1) Increased resources are needed for communication to raise the visibility of vaccine preventable diseases with a focus on measles and rubella Creating and promoting demand for immunization requires a long term investment Communication plans may target many different audiences (e.g., politicians, public health leaders and workers, healthcare providers, parents, etc.). Plans targeting each of these audiences should be developed and audience-specific messages developed and tested 20

Communication - recommendations (2) Data on measles incidence, including complications and deaths, as well as information on the costs associated with outbreaks, should be the focus of educating various audiences about the importance of preventing the illness. Data should be supplemented by stories of actual cases to illustrate the statistical data. Collection of information on cases of CRS can also be a powerful advocacy tool Outbreaks of measles and rubella should be recognized as opportunities to promote the importance of vaccination, with emphasis on measles rubella containing vaccine In advocating for improved prevention of measles and rubella, it will be important to collect stories of how a focus on those diseases not only improved their control but also helped to enhance overall immunization and health systems 21

Research and development -- recommendations (1) Programmatically-oriented operations research, in addition to technologically-oriented research, should be used to determine how best to terminate measles transmission including achieving optimal uptake of vaccination in populations, which populations should be targeted for special immunization efforts, how to optimize surveillance systems, and the economic impact of disease Sustained commitment to adequately funding measles and rubella research is required. An advocacy plan to secure funding should be developed 22

Research and development -- recommendations (2) A working group focusing in a sustained fashion on advocating for, promoting and prioritizing measles and rubella research is critical. The natural home for this group is WHO. 23

Polio transition - recommendations Given the imminent reduction in polio eradication resources, which can have an adverse impact on both measles and rubella control/elimination efforts, a focus on transition of polio resources is urgent and needs to be a top priority All stakeholders involved in control and elimination of measles and rubella should engage in polio transition planning (at all levels) to make the most of the opportunity and avoid the risks of the end of GPEI Strengthening immunization systems and the control and elimination of measles and rubella should be designated as high priorities for polio transition planning and implementation 24

Governance - recommendations It is imperative that there be close collaboration and coordination between Gavi and the M&RI, as a central element in building the overall immunization system and in order to ensure that measles and rubella control and elimination efforts are coordinated and efficient Efforts to control and eliminate measles and rubella should be integrated with the general immunization system and should be used to build and enhance the overall immunization system 25

Resource Mobilization and Advocacy - recommendations (1) A multi-year Financial Resource Requirement (FRR) document for measles and rubella vaccination in the context of overall immunization systems should be developed. It should include demand-driven, countrydriven projections of need, and reflect funding from Gavi, M&RI, and other donors, and domestic financing The recent welcome additional support from Gavi for measles and rubella activities provides a major step forward for achieving measles and rubella goals. However, it is not, in itself, sufficient to provide adequate assistance globally, as many countries are not Gavi-eligible or are graduating from Gavi-eligibility and key global strategies such as surveillance and research are under-resourced. Consequently, there is a need for additional funding 26

Resource Mobilization and Advocacy - recommendations (2) Efforts should be made to identify examples of when a focus on measles and rubella elimination has led to building the overall immunization system. In addition, it is important to remain open to examples of when a focus on measles and rubella has had a negative impact on overall healthcare and immunization systems, and learn from any such examples how such a situation can be avoided. 27

Summary (1) Tremendous progress has been made towards both measles and rubella elimination since 2001. However, despite these advances, neither measles nor rubella elimination are on track The strategies articulated in the strategic plan are sound, but full implementation has been limited by lack of global political will and country ownership In principle, the 2020 goals can still be reached, but doing so would require a substantial escalation of political will and resources and heavy reliance on SIAs 28

Summary (2) This report recommends: Focusing on improving ongoing immunization systems Re-orienting the measles and rubella elimination program to increase emphasis on surveillance Measles incidence should be used as an indicator of the health of the immunization and overall health system Focusing on measles and rubella elimination can result in gains across the immunization system A costed implementation plan should be developed not later than twelve months after the release of this report. 29

Question for the SAGE Does the SAGE endorse the recommendations of the Midterm Review of the Global Measles and Rubella Strategic Plan 2012 2020? 30